{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} New Treatment for Metastatic Colorectal Cancer With Mutated KRAS G12C
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Learning Objectives
After completing this continuing education activity you will be able to:
- Compare progression-free survival and overall response rate in the 3 treatment arms of the phase III CodeBreaK 300 clinical trial.
- Identify safety issues related to the use of sotorasib plus panitumumab.
Learning Outcomes
A majority of the participants of this activity will demonstrate knowledge of the use of sotorasib plus panitumumab as third-line therapy in the management of patients with KRAS G12C metastatic colorectal cancer that has progressed by achieving a passing score on the posttest.Disclosures
All authors, faculty, staff, and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- FL - BON 1.0 CH
- GA - BON 1.0 CH
- NM - BON 1.0 CH
- SC - BON 1.0 CH
- WV - BOERN 1.0 CH
Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0124
Published: January 2024
Expires: 3/6/2026
Sources:
Oncology Times
Required Passing Score: 4/5 (80%)